PULM · Pulmatrix, Inc.
$1.77
+0.08 (+4.73%)
At close · Jul 23
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that, given the Company’s current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued without the closing of the Merger.”View the 10-Q filed May 15, 2026
Market Cap
$6.03M
Shares
3.65M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.81M
0%
FY2025
Net Income
-$5.16M
+46%
FY2025
Operating Margin
-66.22%
+58.8pp
FY2025
Diluted EPS
-$1.41
+46.2%
FY2025
Operating Cash Flow
-$5.43M
+49.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $7.81M | $7.81M | $7.3M | $6.07M | $5.17M | $12.63M | $7.91M | $153K | $335K | $835K | $1.2M | |
| $360K | — | $467K | $867K | $309K | $7000 | — | — | — | — | — | — | |
| $22K | $38K | $7.17M | $15.52M | $18.24M | $15.38M | $15.61M | $12.85M | $12.97M | $10.24M | $10.15M | $7.19M | |
| $4.59M | $5.13M | $7.79M | $6.52M | $6.78M | $6.38M | $6.89M | $8.49M | $7.52M | $7.57M | $8.02M | $17.03M | |
| — | — | — | — | — | — | — | — | — | — | — | $4.53M | |
| — | $106K | $106K | $134K | $162K | $169K | $215K | $182K | $231K | $246K | $250K | $232K | |
| $4.61M | $5.17M | $17.57M | $22.04M | $25.02M | $25.34M | $22.5M | $28.6M | $20.48M | $17.81M | $25.7M | $24.22M | |
| -$4.61M | -$5.17M | -$9.76M | -$14.74M | -$18.95M | -$20.17M | -$9.86M | -$20.69M | -$20.33M | -$17.48M | -$24.87M | -$23.02M | |
| — | -66.22% | -125.07% | -201.97% | -312.09% | -390.15% | -78.06% | -261.59% | -13288.24% | -5216.42% | -2977.96% | -1916.57% | |
| — | -$5.06M | -$9.66M | -$14.61M | -$18.79M | -$20M | -$9.65M | -$20.51M | -$20.1M | -$17.23M | -$24.62M | -$22.79M | |
| — | — | — | — | — | — | — | $186K | $186K | $643K | $881K | $953K | |
| $103K | $144K | $467K | — | — | — | $82K | $301K | — | — | — | — | |
| $88K | $7000 | $204K | $619K | $111K | -$4000 | -$9.45M | $96K | -$232K | $28K | -$2000 | -$44K | |
| — | — | — | — | — | — | — | — | — | -$18.06M | -$30.8M | — | |
| — | $0 | — | — | — | — | — | — | — | -$2.96M | -$2.96M | $0 | |
| -$4.53M | -$5.16M | -$9.56M | -$14.12M | -$18.84M | -$20.17M | -$19.31M | -$20.6M | -$20.56M | -$18.06M | -$27.84M | -$26.17M | |
| — | -66.13% | -122.46% | -193.49% | -310.26% | -390.23% | -152.83% | -260.38% | -13439.87% | -5389.85% | -3334.49% | -2178.77% | |
| — | — | — | — | -$18.84M | -$23.37M | — | — | — | — | -$27.84M | -$26.17M | |
| USD/shares | — | -$1.41 | -$2.62 | -$3.87 | -$5.46 | — | — | — | — | — | — | — |
| USD/shares | — | -$1.41 | -$2.62 | -$3.87 | — | — | — | — | — | — | — | — |
| shares | — | 3.65M | 3.65M | 3.65B | 3.45M | 2.71M | 1.44M | 836.7K | 206.32K | 968.58K | 740.76K | 404.5K |
| shares | — | 3.65M | 3.65M | 3.65B | — | 2.71M | 1.44M | 836.7K | 206.32K | 968.58K | 740.76K | 404.5K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×